





**Supplementary Figure 1.** Th2 cells in blood samples of SLE-SL and SLE-LN patients. A. Th2 cells in blood samples were examined through flow cytometry. B. Expressions of IFNGR1, IFNGR2, pSTAT1 and TBX21 were assessed through Flow cytometry. SLE: systemic lupus erythematosus; HC: healthy control; SL: skin lesion; LN: lupus nephritis.





**Supplementary Figure 2.** B cells in blood samples of SLE-SL and SLE-LN patients. B cells in blood samples were assessed by Flow cytometry. \*\*\*P<0.001 vs. HC group. SLE: systemic lupus erythematosus; HC: healthy controls; SL: skin lesion; LN: lupus nephritis.











**Supplementary Figure 5.** B cells increased in blood and spleen samples from SLE mouse models. A, B. B cells were assessed in blood and spleen samples through Flow cytometry. \*\*\*P<0.001 vs. HC group; ###P<0.001 vs. SLE-LN group; &&&P<0.001 vs. SLE-LN+sh-NC group. SLE: systemic lupus erythematosus; HC: healthy controls; LN: lupus nephritis; NC: negative controls.